Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data
11:28am, Thursday, 11'th Nov 2021
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Remdesivir-Linked Covid-19 Mutation Found In Immunocompromised Patient
05:46am, Thursday, 11'th Nov 2021
The mutated version of the virus exhibited resistance to the antiviral drug remdesivir.
Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®
10:00am, Tuesday, 09'th Nov 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new clinical and real-world data at the American Association for the Study of Liver Disea
Gritstone Poised To Dominate mRNA Market
12:57am, Monday, 08'th Nov 2021
Gritstone Poised To Dominate mRNA Market
How Are Biotech ETFs Reacting to These Q3 Earnings Releases?
12:50am, Saturday, 06'th Nov 2021
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Big Quarter for Gilead's Covid Drug Fails to Boost Stock
05:13pm, Thursday, 04'th Nov 2021
A blowout third quarter did little to ignite the shares of Gilead Sciences Inc. ( GILD , Financial) as investors seemed to be spooked by concerns over the staying power of the company's antiviral drug
Gilead Is A Solidly Profitable, High Dividend-Yielding Stock
07:26am, Wednesday, 03'rd Nov 2021
Gilead Is A Solidly Profitable, High Dividend-Yielding Stock
